Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gemtuzumab ozogamicin in acute myeloid leukemia.

Leukemia - 1 Sept 2017

Godwin C D, Gale R P, Walter R B

Abstract excerpt

CD33 is variably expressed on leukemia blasts in almost all patients with acute myeloid leukemia (AML) and possibly leukemia stem cells in some. Efforts to target CD33 therapeutically have focused on gemtuzumab ozogamicin (GO; Mylotarg), an antibody-drug conjugate delivering a DNA-damaging calicheamicin derivative. GO is most effective in acute promyelocytic leukemia but induces remissions in other AML types and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoglycosides
Share to Antibodies, Monoclonal, Humanized
Share to Genotype

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Polymorphism, Single Nucleotide

Share to Prognosis

Share to Sialic Acid Binding Ig-like Lectin 3

Source

Open in PubMed Open full text

Identifiers

PMID: 28607471
DOI: 10.1038/leu.2017.187
PMCID: PMC13345506

Genes

CD33

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gemtuzumab ozogamicin in acute myeloid leukemia.PMID 28607471Read ↗

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia TreatmentSemantic proximity Read ↗

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.Semantic proximity Read ↗

Analysis of Clinical Impact of CD33 rs12459419 Single-Nucleotide Polymorphism in AML Treated with Intensive Chemotherapy Without Gemtuzumab Ozogamicin.Semantic proximity Read ↗

Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children’s Oncology Group AAML0531 TrialSemantic proximity Read ↗

Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy.Semantic proximity Read ↗

Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis.Semantic proximity Read ↗

No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.Semantic proximity Read ↗

Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot studySemantic proximity Read ↗

Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia.Semantic proximity Read ↗

High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia.Semantic proximity Read ↗

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.